Strive Financial Group’s Ionis Pharmaceuticals IONS Stock Holding History

Strive Financial Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.38K	Buy	+31	New	+$1.76K	﹤0.01%	999

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Tweedy, Browne Co Stamford, Connecticut $1.23B AUM 16.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Strive Financial Group's IONS Position: Q3 2026 in Review

Strive Financial Group opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2026: 31 shares worth $1.38K. The stake represents ﹤0.01% of the portfolio and ranks #999 among its holdings.

227 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

Strive Financial Group held 31 shares of Ionis Pharmaceuticals worth $1.38K as of Q3 2026.
Ionis Pharmaceuticals was a new Strive Financial Group position in Q3 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Strive Financial Group's portfolio in Q3 2026, its #999 holding.
227 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Strive Financial Group's 13F filing for Q3 2026, filed 9 Nov 2026.